Company: STAA
Filing Date: 2025-09-15
Form Type: PREC14A
Source: 0001213900-25-087448
Chunk: 5

Company: STAAR SURGICAL CO
Filing Date: 2025-09-15
Form: PREC14A
Chunk 5
---
’s
stockholders approve the Merger Agreement Proposal. For the reasons discussed in this Proxy Statement, we OPPOSE the Proposed Merger
and the approval of the Merger Agreement Proposal. To that end, we are soliciting your proxy to vote “AGAINST” the
Merger Agreement Proposal.

We recommend that you demonstrate
your opposition to the Merger Agreement Proposal and send a message to the Board that the Merger Agreement Proposal is NOT in the
best interests of stockholders by using the enclosed GREEN Proxy Card to vote via the Internet or by telephone today. Alternatively,
you may complete, sign, date and promptly return the enclosed GREEN Proxy Card in the postage-paid envelope provided.

If you have any questions
or require any assistance with voting your shares, please contact our proxy solicitor, [●], by calling [●] or toll free
at [●], or by email at [●].

<div align='center'>Reasons to Vote
Against the Merger Agreement PROPOSAL</div>

Broadwood has been a committed
investor in, and strong supporter of, STAAR for more than thirty years. We have provided capital to the Company on various occasions and
have purchased a substantial number of additional shares as recently as a few months ago. Today, we beneficially own approximately 27.4%
of STAAR’s outstanding shares, making us the Company’s largest stockholder by a significant margin.

We initially invested in STAAR
more than three decades ago, and have added to our position over time, because we strongly believe in the Company’s ability to create
substantial long-term value for stockholders. We believe STAAR’s superior and proprietary technology, as well as its global scale,
position the Company to take a significant portion of the refractive surgery market, become a highly profitable enterprise and, ultimately,
deliver upon its vision to be the first choice for surgeons and patients seeking visual freedom from glasses and contact lenses.

We share management’s
view that the Company’s near-term challenges with respect to inventory, tariffs, and other issues are transitory,1
and we regard them as unlikely to materially diminish the long-term value of the business. In fact, we believe that those challenges
have already been substantially resolved2
and that the Company is poised to return to growth and achieve sustained profitability. Furthermore, recent clinical data indicate that
the advantages of STAAR’s technology over laser refractive surgery technologies are greater than was previously recognized3
which, in our view, suggests that the Company’s